Cell Therapy
Cell therapy is the administration of viable, often purified cells into a patient’s body to grow, replace, or repair damaged tissue for the treatment of a disease. A variety of different types of cells can be used in cell therapy, including pluripotent stem cells (induced and embryonic), hematopoietic (blood-forming) stem cells, modified immune cells, skeletal muscle stem cells, neural stem cells, mesenchymal stem cells (adult stem cells that differentiate into structures as connective tissues, blood, lymphatics, bone, and cartilage), lymphocytes, dendritic cells, and pancreatic islet cells.
Members of the Adjuvant team serve as advisors for the Alliance for Regenerative Medicine. Morrie Ruffin, the Managing Director of Adjuvant, is a founder ARM.
Gene Therapy & Gene Editing
Gene therapy seeks to modify or introduce genes into a patient’s body with the goal of durably treating, preventing or potentially even curing disease, including several types of cancer, viral diseases, and inherited disorders. Gene therapy approaches include replacing a mutated gene that causes disease with a functional copy, introducing a new, correct copy of a gene into the body in order to fight disease; or editing a specific gene or genes to address the underlying cause of a disease.
Members of the Adjuvant team serve as advisors for the Alliance for Regenerative Medicine. Morrie Ruffin, the Managing Director of Adjuvant, is a founder ARM.
Tissue Engineering & Biomaterials
Tissue engineering seeks to restore, maintain, improve, or replace damaged tissues and organs through the combination of scaffolds, cells, and/or biologically active molecules. Tissue engineering often begins with a scaffold, which may utilize any of a number of potential materials, from naturally occurring proteins to biocompatible synthetic polymers. Certain tissue engineering therapies may utilize an existing scaffold by removing the cells from a donor organ, a process called decellularization, until only the pre-existing protein-based scaffold or extracellular matrix (ECM) remains. Cells—and in some cases, additional growth factors to encourage the cells to take root—are added, allowing a tissue or organ to develop and grow ex-vivo. Biomaterials include any substance engineered to interact with a patient’s living biological system for a medical purpose. These biomaterials often provide support as a physical structure for engineered tissues.
Artificial Intelligence in Healthcare
Artificial Intelligence is the broader concept of machines being able to carry out tasks in a way that we would consider “smart”. Machine Learning is a subset of AI based around the concept of iterative learning in which a system ‘learns’ from data input and modifies activity without human intervention. Artificial intelligence in healthcare is the application of machine learning to medical information through the analysis of complex algorithms and software to enable data-driven solutions.
Adjuvant is currently managing the operations of the Alliance for Artificial Intelligence in Healthcare.
Government Relations
Government relations is the general terminology for identifying and engaging appropriate stakeholders within government agencies. This can take the form of advocacy, education, and network development and is a key component of any private organization seeking government partners or funding.
For life sciences government relations services, Adjuvant partners with industry leaders such as Cardinal Point, Health Policy Strategies, Inc. and Holland & Knight.
Commercial Strategy & Communications
Commercial strategy encompasses many components of the mission and operating principles for any company. This includes a corporate business plan, fundraising approach, communications strategy value proposition, partnering prioritization, and go-to-market strategy. A clear and forward-looking commercial strategy can be a pillar of strength for a company, allowing for dynamic reaction to external events and laying the ground work for robust growth.
